In a clinical test, two new drugs have shown extraordinary results at treating Ebola. The survival rate of patients has increased largely. Considering the outbreak of Ebola in the Democratic Republic of the Congo, this is seen as a turning point.
Ebola was first witnessed 40 years ago. It killed more than 11,000 people between 2014 and 2016 in West Africa; from then there were smaller outbreaks in many parts of Africa. The current outbreak in Congo is one among them. The current outbreak has killed more than 1800 people.
“From now on we will no longer say that Ebola is not curable. This advance will in the future help save thousands of lives that would have had a fatal outcome in the past,” Jean-Jacques Muyembe, director-general of the Democratic Republic of the Congo’s Institut National de Recherche Biomedical, announced in a press call.
Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, which is part of the National Institutes of Health, explained to The Verge that when a situation is severe, they are forced to deploy drugs which are promising but lack rigorous clinical trials to prove their safety and efficiency. This trial is proof that even in the most severe cases studies can be conducted to ensure the safety of the drug.
This is the first time that a randomized, controlled trial has shown quickly and successfully what the best drugs are in the middle of an ongoing outbreak,” says Anthony Fauci
700 patients were enlisted by Congo and international medical organizations to try four drugs such as REGN-EB3, mAb114, receiver, and ZMapp. REGN-EB3 and mAb114 are found more promising; due to which redeliver and ZMapp will no longer be used. REGN-EB3, mAb114 will be given free for “Compassionate use”. Even though these two drugs are still experimental, it gives hope to humanity